Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

9780323896924
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 14 DAYS
483.79 zł
411.22 zł Save 72.57 zł Tax included
Lowest price within 30 days before promotion: 411.22 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include:: Chronic Lymphocytic Leukemia:: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Product Details
Elsevier
91675
9780323896924
9780323896924

Data sheet

Publication date
2021
Issue number
1
Cover
hard cover
Pages count
240
Weight (g)
480
  • Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia
    The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications
    Prognostic and Predictive Implications of Cytogenetics and Genomics
    Genomics of Resistance to Targeted Therapies
    First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond
    Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib
    Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Brutons Tyrosine Kinase Inhibitors
    The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
    Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
    Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
Comments (0)

  • Frequently purchased together

    No products available